NCT00727064

Study Evaluating the Pharmacokinetics of Venlafaxine Extended-Release (ER) and Desvenlafaxine Succinate Sustained-Release (DVS SR) 50 mg in Healthy Subjects

A Randomized, Open-Label, Two-Period, Parallel Group, Crossover Study to Evaluate the Pharmacokinetics of Venlafaxine Extended-Release and DVS SR in Healthy Subjects Who Are Extensive or Poor Cytochrome P450 2D6 Substrate Metabolizers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 14 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine if the relative difference in Pharmacokinetics (PK) between extensive metabolizers (EMs) and poor metabolizers (PMs) is the same with desvenlafaxine SR and venlafaxine ER when a single dose is administered.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Desvenlafaxine Succinate Sustained-Release (DVS SR)
DRUG	Venlafaxine Extended Release (VEN ER)

Timeline

• Start date: 2008-06-01
• Primary completion: 2008-08-01
• Completion: 2008-08-01
• First posted: 2008-08-01
• Last updated: 2010-06-02
• Results posted: 2010-04-19

Locations

1 site across 1 country: United States